相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。CTLA-4 blockade increases antigen-specific CD8+ T cells in prevaccinated patients with melanoma: three cases
Jianda Yuan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Phase I/II trial of a dendritic cell vaccine transfected with DNA encoding melan A and gp100 for patients with metastatic melanoma
J. C. Steele et al.
GENE THERAPY (2011)
Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
Paul F. Robbins et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Recent Developments in Cancer Vaccines
Karolina Palucka et al.
JOURNAL OF IMMUNOLOGY (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Split T Cell Tolerance against a Self/Tumor Antigen: Spontaneous CD4+ but Not CD8+ T Cell Responses against p53 in Cancer Patients and Healthy Donors
Takemasa Tsuji et al.
PLOS ONE (2011)
Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals
Jun Mitsui et al.
CLINICAL CANCER RESEARCH (2010)
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Philip W. Kantoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients
Julien Fourcade et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
Jedd D. Wolchok et al.
LANCET ONCOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation
Adam D. Cohen et al.
PLOS ONE (2010)
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
Junko Matsuzaki et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Integrated Data From 2 Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trials of Active Cellular Immunotherapy With Sipuleucel-T in Advanced Prostate Cancer
Celestia S. Higano et al.
CANCER (2009)
Potentiating Endogenous Antitumor Immunity to Prostate Cancer through Combination Immunotherapy with CTLA4 Blockade and GM-CSF
Lawrence Fong et al.
CANCER RESEARCH (2009)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
Jeffrey Weber et al.
CLINICAL CANCER RESEARCH (2009)
Adoptive cell therapy for the treatment of patients with metastatic melanoma
Steven A. Rosenberg et al.
CURRENT OPINION IN IMMUNOLOGY (2009)
Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses
Yun Lin et al.
CYTOTHERAPY (2009)
PD-1 Is a Regulator of NY-ESO-1-Specific CD8+ T Cell Expansion in Melanoma Patients
Julien Fourcade et al.
JOURNAL OF IMMUNOLOGY (2009)
No Correlation Between Clinical Response to CTLA-4 Blockade and Presence of NY-ESO-1 Antibody in Patients With Metastatic Melanoma
Stephanie L. Goff et al.
JOURNAL OF IMMUNOTHERAPY (2009)
Myeloid-derived suppressor cells as regulators of the immune system
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant
Sylvia Adams et al.
JOURNAL OF IMMUNOLOGY (2008)
Treatment of metastatic melanoma with autologous CD4+T cells against NY-ESO-1
Naomi N. Hunder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit
Jianda Yuan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
F. Stephen Hodi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma
Jedd D. Wolchok et al.
MOLECULAR THERAPY (2007)
Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming
Danila Valmori et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Recombinant vaccinia/fowipox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients
Elke Jaeger et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Dendritic cell surface calreticulin is a receptor for NY-ESO-1: Direct interactions between tumor-associated antigen and the innate immune system
Gang Zeng et al.
JOURNAL OF IMMUNOLOGY (2006)
Tumor antigen expression in melanoma varies according to antigen and stage
C Barrow et al.
CLINICAL CANCER RESEARCH (2006)
Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909
DE Speiser et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans
ID Davis et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
The three Es of cancer immunoediting
GP Dunn et al.
ANNUAL REVIEW OF IMMUNOLOGY (2004)
Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients:: Correlation with antibody responses
S Gnjatic et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Analysis of the B-cell repertoire against antigens expressed by human neoplasms
KD Preuss et al.
IMMUNOLOGICAL REVIEWS (2002)
Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations
Y Nagata et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues
AA Jungbluth et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Induction of primary NY-ESO-1 immunity:: CD8+T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+cancers
E Jäger et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Monitoring CD8 T cell responses to NY-ESO-1:: Correlation of humoral and cellular immune responses
E Jäger et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)